ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2015
Elevated plasma interleukin-35 levels predict poor prognosis in patients with non-small cell lung cancer.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Overexpression of interleukin-35 associates with hepatocellular carcinoma aggressiveness and recurrence after curative resection.British journal of cancer · 2016Trial
- Elevated Plasma Interleukin-35 as a Prognostic Indicator in Localized Clear Cell Renal Cell Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Correlation Analysis Among the Level of IL-35, Microvessel Density, Lymphatic Vessel Density, and Prognosis in Non-Small Cell Lung Cancer.Clinical and translational science · 2021Observational
- IL35 predicts prognosis in gastric cancer and is associated with angiogenesis by altering TIMP1, PAI1 and IGFBP1.FEBS open bio · 2020Article
- Interleukin-35 promotes progression of prostate cancer and inhibits anti-tumour immunity.Cancer cell international · 2020Article
- Interleukin-35 is associated with the tumorigenesis and progression of prostate cancer.Oncology letters · 2019Article
- Interleukin-35 as an Emerging Player in Tumor Microenvironment.Journal of Cancer · 2019Review
- IL-35 induces N2 phenotype of neutrophils to promote tumor growth.Oncotarget · 2017Article
- IL-35 expression is increased in laryngeal squamous cell carcinoma and in the peripheral blood of patients.Oncology letters · 2017Article
- Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent.Mediators of inflammation · 2017Review
- Interleukin-35-Producing CD8αFrontiers in immunology · 2017Article
- Interleukin-35 as a predictor of prostate cancer in patients undergoing initial prostate biopsy.OncoTargets and therapy · 2017Article
- The renal level of a novel cytokine IL-35 is related to sepsis-associated acute kidney injury in mice.International journal of clinical and experimental pathology · 2017Article
- Plasma Level of Interleukin-35 as an Independent Prognostic Indicator in Hepatocellular Carcinoma.Digestive diseases and sciences · 2016Article
- [Current Research of the Roles of IL-35 in Tumor Progression].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Review
- Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosisin breast cancer.American journal of translational research · 2016Article
- Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis.PloS one · 2015Article
- Elevated serum interleukin-35 levels correlate with poor prognosis in patients with clear cell renal cell carcinoma.International journal of clinical and experimental medicine · 2015Article
- Association of Human Interleukin-35 Level in Gingival Crevicular Fluid and Serum in Periodontal Health, Disease, and after Nonsurgical Therapy: A Comparative Study.Contemporary clinical dentistryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interleukin-35 (IL-35) has recently been implicated in tumor immunity. The aim of this study was to explore the clinical role of plasma IL-35 in patients with non-small cell lung cancer (NSCLC). Plasma collected from 106 patients with NSCLC cases and 78 healthy controls (HC) were subjected to IL-35 enzyme-linked immunosorbent assay (ELISA) and relationships between plasma IL-35 levels and clinical characteristics were evaluated. The correlation of IL-35 and overall survival was analyzed using Kaplan-Meier method. The prognostic value of IL-35 was tested using univariate and multivariate analysis. Circulating IL-35 levels were significantly higher in the NSCLC group in comparison with the HC group (21.37 ± 11.55 pg/ml vs. 10.09 ± 5.32 pg/ml, p < 0.001). Correlation analysis by subgroup indicated that plasma IL-35 correlated positively with tumor TNM stage (p < 0.001) and lymph node metastases (p < 0.0001). Using a cutoff level of 20.26 pg/ml (median value), IL-35 showed an inverse correlation with overall survival. Univariate and multivariate analysis indicated that plasma IL-35 was an independent prognostic factor for NSCLC patients. Circulating IL-35 in NSCLC patients significantly increased. IL-35 is a promising potential biomarker in prognostication of clinical outcome of NSCLC patients and the regulation of IL-35 expression may provide a new target for the treatment of NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.